Hiroshi Watanabe Johnson & Johnson ( NYSE: JNJ ) said a new analysis of phase 3 data found that a combination of Rybrevant (amivantamab) and Leclaza (lazertinib) led to longer progression-free survival in subgroups of patients with a certain type of non-small cell lung cancer compared to AstraZeneca's Tagrisso (osimertinib) Patients in the MARIPOSA study, all of whom were treatment-naive, had epidermal growth factor receptor (EGFR)-mutated NSCLC. The company noted 85% of these patients have high-risk disease. In patients with a history of brain metastases, those who received the combination had a 31% reduction in the risk of disease progression or death compared to those on Tagrisso.
For those who had liver metastases, the figure was 42%. In a separate study, a subcutaneous version of Rybrevant was found to be non-inferior to the current intravenous formulation. J&J added that an application for the subcutaneous version was submitted to the European Medicines Agency.
More on Johnson & Johnson Johnson & Johnson: Market Will Regret The Overreaction Johnson & Johnson: Vital Signs Decent, A Compelling Value Case J&J completes acquisition of cardiac device maker Shockwave Johnson & Johnson depression candidate seltorexant meets phase 3 goals Johnson & Johnson (JNJ) Bernstein's 40th Annual Strategic Decisions Conference - (Transcript).
